Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT06753565 Sponsor: German University in Cairo Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT06753565
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 60 years old
  • You have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints) for at least 6 months, based on recognized medical guidelines
  • You have been taking one or more standard arthritis medications (called DMARDs) for at least 6 months, with your dose staying the same for at least 1 month before the study starts
  • Your rheumatoid arthritis is still active and not fully controlled, even while taking your current arthritis medications (confirm with trial site)
  • You, or your legal representative, are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • You are currently pregnant or breastfeeding
  • You have liver problems, where certain liver-related blood test results are higher than 1.5 times the normal level
  • You have kidney problems, shown by a specific blood test result being above a certain level (confirm with trial site)
  • You currently have an active infection or any form of cancer
  • You have other medical conditions that are not well controlled, or you have another rheumatic disease (a disease affecting joints or connective tissue)
  • You are currently taking a blood-thinning medication called warfarin, or other drugs that may interact with a supplement called carnitine (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +2001223360548

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
German University in Cairo
Registry
ClinicalTrials.gov
Start date
31 December 2024
Est. completion
1 June 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

change in DAS28 ESR for both arms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov